Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the literature about the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of cardiac disorders, specifically myocardial infarction (MI) and heart failure (HF). Data Sources: Searches were conducted in MEDLINE (1946-May 2016) and Excerpta Medica (1980-May 2016) using EMBASE with the search terms glucagon-like peptide 1, exenatide, albiglutide, liraglutide, dulaglutide, myocardial infarction, heart failure, and cardiovascular. The references of relevant articles were reviewed to identify additional citations. Study Selection and Data Extraction: Clinical trials were limited to the English language and human trials. In all, 18 trials explored the use of GLP-1 RAs in the treatment of cardiac disorders in patients with and without diabetes mellitus. Data Synthesis: Of the 18 trials reviewed, 11 trials studied the impact of GLP-1 RAs in MI. All showed a significant beneficial effect on various cardiac parameters. Favorable outcome improvements included myocardial blood flow, left ventricular (LV) function, and MI size. Seven trials reviewed the use of GLP-1 RAs in the treatment of HF. Three trials showed significant improvements in LV ejection fraction, cardiac index, and peak oxygen consumption. Conclusions: Limited data suggest that GLP-1 RAs may be effective for the treatment of cardiac disorders in patients with and without diabetes mellitus. These studies suggest that GLP-1 RAs may have potential pleiotropic beneficial effects in patients with cardiovascular disease beyond their role in managing diabetes. These medications may be cardioprotective after a MI but are less promising in HF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“One mechanism of action of GLP-1 RAs in type 2 diabetes involves binding to receptors in the β cells, which leads to stimulation of insulin secretion.(1) Current GLP-1 RAs include exenatide (Byetta, Bydureon), dulaglutide (Trulicity), albiglutide (Tanzeum), liraglutide (Victoza), and the recently approved lixisenatide…”
BackgroundGrundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Diabetes and cardiovascular disease
Howard, B. V., & Magee, M. F. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0046-8 · Cited by 1,381
Research works printed but not linked: 1
- Margulies KB, Paper presented at: American Heart Association 2015 Scientific Sessions
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
“GLP-1R activation affects renal function [83] and has pleiotropic cardioprotective effects [84].”
BackgroundPenna, C. R. R., Andreadou, I., Aragno, M., Beauloye, C., Bertrand, L., Lazou, A., Falcão‐Pires, I., Bell, R., Zuurbier, C. J., Pagliaro, P., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14993 · Cited by 114
“These medications may be cardioprotective after an AMI but are less promising in heart failure (HF) et al., 2016; reviewed in Wroge and Williams, 2016).”
The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
Recio, C., Μaione, F., Iqbal, A. J., Mascolo, N., & Feo, V. D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00526 · Cited by 123
“Interestingly, besides regulation of glucose homeostasis, GLP-1 mimetic peptides have also been shown to exert cardioprotective effects in cardiovascular-related death, nonfatal MI, and non-fatal stroke (Advani et al., 2013; Wroge and Williams, 2016).”
BackgroundCardiac metabolism — A promising therapeutic target for heart failure
Noordali, H., Loudon, B. L., Frenneaux, M. P., & Madhani, M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.001 · Cited by 104
Metadata
- Authors
- Wroge, J., & Williams, N. T.
- Affiliations
- Southwestern Oklahoma State University (US)
- Corresponding author
- Williams, Nancy Toedter
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2016-08-20
- Volume
- 50
- Issue
- 12
- Pages
- 1041-1050
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2509831471
- Semantic Scholar
- 41b455ea68de346dbda5dcf1481cf6fe09b1affd
- Cited by
- 17
- References
- 64
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 1 · 2017: 5 · 2016: 1
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- GLP-1 receptor agonists, myocardial infarction, heart failure, cardioprotection, exenatide, liraglutide, dulaglutide, albiglutide, left ventricular function, diabetes mellitus, cardiovascular disease
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Peptides, Recombinant Fusion Proteins, Venoms, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. https://app.cochat.ai/papers/10.1177/1060028016663218
- The paper
- Wroge, J., & Williams, N. T. (2016). Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028016663218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.